BioCentury
ARTICLE | Company News

Tranzyme gastrointestinal news

February 18, 2013 8:00 AM UTC

Tranzyme's board said the company will explore strategic alternatives, including a possible merger, sale or other business transaction. Stifel is advising the company and Skadden, Arps, Slate, Meagher & Flom is legal counsel. The company, which said there is no set timetable for the review process, declined to provide details. At Sept. 20, 2012, the company had about $40.8 million in cash and a nine-month operating loss of $16.1 million. ...